Advertisement
Australia markets closed

  • ALL ORDS

    7,970.80
    +74.90 (+0.95%)
     

  • ASX 200

    7,701.70
    +73.50 (+0.96%)
     

  • AUD/USD

    0.6655
    +0.0021 (+0.31%)
     

  • OIL

    77.18
    -0.73 (-0.94%)
     

  • GOLD

    2,347.70
    -18.80 (-0.79%)
     

  • Bitcoin AUD

    101,549.11
    +1,060.55 (+1.06%)
     

  • CMC Crypto 200

    1,423.80
    -4.77 (-0.33%)
     

  • AUD/EUR

    0.6132
    +0.0014 (+0.23%)
     

  • AUD/NZD

    1.0824
    -0.0020 (-0.19%)
     

  • NZX 50

    11,867.29
    +310.08 (+2.68%)
     

  • NASDAQ

    18,536.65
    -2.01 (-0.01%)
     

  • FTSE

    8,275.38
    +44.33 (+0.54%)
     

  • Dow Jones

    38,686.32
    +574.84 (+1.51%)
     

  • DAX

    18,497.94
    +1.15 (+0.01%)
     

  • Hang Seng

    18,079.61
    -150.58 (-0.83%)
     

  • NIKKEI 225

    38,487.90
    +433.77 (+1.14%)
     

Talphera to Participate at A.G.P. Virtual Healthcare Conference

PR Newswire
·1-min read

SAN MATEO, Calif., May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET.

Presentation Information
Presentation Date: Tuesday, May 21, 2024
Presentation Time: 10:40 am ET
Format: Fireside Chat Webcast link: Click here

About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Talphera Logo (PRNewsfoto/Talphera, Inc.)
Talphera Logo (PRNewsfoto/Talphera, Inc.)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-at-agp-virtual-healthcare-conference-302148401.html

SOURCE Talphera, Inc.